Radiolabeled J591 antibody delivers lethal hit to advance prostate cancers in a phase I trail.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology / Q000378:metabolism; D043425:Glutamate Carboxypeptidase II / Q000276:immunology / Q000378:metabolism; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000556:secondary; D016499:Radioimmunotherapy
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000922:Immunotoxins; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II